Strahlentherapie und Onkologie

, Volume 190, Issue 5, pp 444–450 | Cite as

Accelerated partial breast irradiation with external beam three-dimensional conformal radiotherapy

Five-year results of a prospective phase II clinical study
  • Emöke Mózsa
  • Norbert Mészáros
  • Tibor Major
  • Georgina Fröhlich
  • Gábor Stelczer
  • Zoltán Sulyok
  • János Fodor
  • Csaba PolgárEmail author
Original article



The aim of this study was to report the 5-year results of accelerated partial breast irradiation (APBI) using external beam three-dimensional conformal radiotherapy (3D-CRT).

Patients and methods

Between 2006 and 2011, 44 patients with low-risk, stage I–II breast cancer underwent breast-conserving surgery. Postoperative APBI was given by means of 3D-CRT using three to five non-coplanar fields. The total dose of APBI was 36.9 Gy (nine fractions of  4.1 Gy b.i.d.). The mean follow-up time was 58.2 months for surviving patients. Survival results, side effects, and cosmetic results were assessed.


One (2.3 %) local recurrence was observed, for a 5-year actuarial rate of 3.7 %. Neither regional nor distant failure was observed. Two patients died of internal disease. The 5-year disease-free, cancer-specific, and overall survival rates were 96.3, 100, and 95.1 %, respectively. Acute side effects included grade 1 (G1) erythema in 75 %, G1 parenchymal induration in 46 %, and G1 pain in 46 % of patients. No G2 or higher acute side effect occurred. Late side effects included G1, G2, and G3 fibrosis in 44, 7, and 2 % of patients, respectively, G1 skin pigmentation in 12 %, and G1 pain in 2 %. Asymptomatic fat necrosis occurred in 14 %. Cosmetic results were rated excellent or good in 86 % of cases by the patients themselves and 84 % by the physicians.


The 5-year local tumor control, toxicity profile, and cosmetic results of APBI delivered with external beam 3D-CRT are encouraging and comparable to other APBI series.


Breast cancer Accelerated partial breast irradiation Three-dimensional conformal radiotherapy Phase II clinical trial Tumor control 

Akzelerierte perkutane dreidimensionale konformale Teilbrustbestrahlung

5-Jahres-Ergebnisse einer prospektiven Phase-II-Studie



Evaluation der 5-Jahres-Ergebnisse bezüglich Überleben, Tumorkontrolle, Nebenwirkungen und Kosmetik nach Teilbrustbestrahlung (APBI) mittels 3-D-konformaler, akzelerierter Radiotherapie (3D-CRT).

Patienten und Methoden

Zwischen 2006 und 2011 wurden 44 Patienten mit Brustkrebs im Stadium I–II und niedrigem Risikoprofil brusterhaltend operiert. Die adjuvante, 3-D-konformale APBI wurde mittels 3–5 nonkoplanarer Feldern durchgeführt. Die Gesamtdosis betrug 36,9 Gy bei 9 -mal  4,1 Gy b.i.d.. Nach einer mittleren Nachbeobachtungszeit von 58,2 Monaten wurden die Überlebensrate, die Tumorkontrolle, die Nebenwirkungen und die Kosmetik evaluiert.


Lediglich ein Lokalrezidiv wurde nachgewiesen (2,3 %) bei einer statistischen 5-Jahres-Rate von 3,7 %. Keine weiteren lokoregionären Rezidive oder Fernmetastasen wurden beobachtet. Es verstarben 2 Patientinnen aufgrund internistischer Erkrankungen. Das krankheitsfreie-, tumorspezifische- und 5-Jahres-Gesamtüberleben war 96,3, 100 und 95,1 %. Es wurden lediglich Grad-1 Akutnebenwirkungen beobachtet: Erythem in 75 %, parenchymale Induration in 46 % und Schmerzen in 46 %, jedoch keine höhergradigen Akuttoxizitäten. An chronischen Nebenwirkungen Grad-1 wurden Hyperpigmentation in 12 %, Schmerzen in 2 % und Fibrosen in 44 % diagnostiziert, Letztere entwickelte sich auch höhergradig (Grad 2 in 7 %, Grad 3 in 2 %). Asymtomatische Fettnekrosen traten in 14 % auf. Die Kosmetik wurde von 86 % der Patientinnen als ausgezeichnet/gut beurteilt, von den Ärzten in 84 %.


Die lokale Kontrolle nach 5 Jahren, die Toxizität und die Kosmetik nach APBI mittels 3-D-konformaler Radiotherapie ist ermutigend und unsere Beobachtung entspricht den Daten anderer APBI-Veröffentlichungen.


Brustkrebs Akzelerierte Teilbrustbestrahlung Dreidimensionale konformale Radiotherapie Klinische Phase-II-Studie Tumorkontrolle 



The trial was registered at with an Identifier number of NCT02003560. We acknowledge the contributions of Katalin Lövey MD and Levente Jánváry MD, who previously worked on the trial, treated patients, and contributed to follow-up of patients and data collection.


  1. 1.
    Barry M, Ho A, Morrow M (2013) The evolving role of partial breast irradiation in early-stage breast cancer. Ann Surg Oncol 20:2534–2540PubMedCrossRefGoogle Scholar
  2. 2.
    Bartelink H, Bourgier C, Elkhuizen P (2012) Has partial breast irradiation by IORT or brachytherapy been prematurely introduced into the clinic? Radiother Oncol 104:139–142PubMedCrossRefGoogle Scholar
  3. 3.
    Berrang TS, Olivotto I, Kim DH et al (2011) Three-year outcomes of a Canadian multicenter study of accelerated partial breast irradiation using conformal radiation therapy. Int J Radiat Oncol Biol Phys 81:1220–1227PubMedCrossRefGoogle Scholar
  4. 4.
    Bourgier C, Acevedo-Henao C, Dunant A et al (2012) Higher toxicity with 42 Gy in 10 fractions as a total dose for 3D-confromal accelerated partial breast irradiation: results from a dose escalation phase II trial. Radiat Oncol 7:141. doi:10.1186/1748-717X-7-141PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Chafe S, Moughan J, McCormick B et al (2013) Late toxicity and patient self-assessment of breast appearance/satisfaction on RTOG 0319: a phase 2 trial of 3-dimensional conformal radiation therapy-accelerated partial breast irradiation following lumpectomy for stages I and II breast cancer. Int J Radiat Oncol Biol Phys 86:854–859Google Scholar
  6. 6.
    Chen PY, Wallace M, Mitchell C et al (2009) Four-year efficacy, cosmesis and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 76:1–7CrossRefGoogle Scholar
  7. 7.
    Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346PubMedCrossRefGoogle Scholar
  8. 8.
    Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New Engl J Med 347:1233–1241PubMedCrossRefGoogle Scholar
  9. 9.
    Formenti SC, Hsu H, Fenton-Kerimian M et al (2012) Prone accelerated partial breast irradiation after breast-conserving surgery: Five-year results of 100 patients. Int J Radiat Oncol Biol Phys 84:606–611PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Harris J, Levine M, Svensson G et al (1979) Analysis of cosmetic results following primary radiation therapy for stage I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys 5:257–261PubMedCrossRefGoogle Scholar
  11. 11.
    Hepel JT, Tokita M, MacAusland SG et al (2009) Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 75:1290–1296PubMedCrossRefGoogle Scholar
  12. 12.
    Jagsi R, Ben-David MA, Moran JM et al (2010) Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys 76:71–78PubMedCrossRefGoogle Scholar
  13. 13.
    Johansson B, Karlsson L, Liljegren G et al (2009) Pulsed dose rate brachytherapy as the sole adjuvant radiotherapy after breast-conserving surgery of T1-T2 breast cancer: First long time results from a clinical study. Radiother Oncol 90:30–35PubMedCrossRefGoogle Scholar
  14. 14.
    Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481Google Scholar
  15. 15.
    Landis DM, Luo W, Song J et al (2007) Variability among breast radiation oncologists in delineation of the postsurgical lumpectomy cavity. Int J Radiat Oncol Biol Phys 67:1299–1308PubMedCrossRefGoogle Scholar
  16. 16.
    Lei RY, Leonard CE, Howell CE et al (2013) Four-year clinical update from a prospective trial of accelerated breast intensity-modulated radiotherapy (APBIMRT). Breast Cancer Res Treat 140:119–133Google Scholar
  17. 17.
    Leonard KL, Hepel JT, Hiatt JR et al (2013) The effect of dose-volume parameters and interfraction interval on cosmetic outcome and toxicity after 3-dimensional conformal accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 85:623–629PubMedCrossRefGoogle Scholar
  18. 18.
    Lewin AA, Derhagopian R, Saigal K et al (2012) Accelerated partial breast irradiation is safe and effective using intensity-modulated radiation therapy in selected early-stage breast cancer. Int J Radiat Oncol Biol Phys 82:2104–2110PubMedCrossRefGoogle Scholar
  19. 19.
    Olivotto IA, Whelan TJ, Parpia S et al (2013) Interim cosmetic and toxicity results from RAPID: A randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol 31:4038–4045Google Scholar
  20. 20.
    Pashtan IM, Recht A, Ancukiewicz M et al (2012) External beam accelerated partial-breast irradiation using 32 Gy in 8 twice-daily fractions: 5-year results of a prospective study. Int J Radiat Oncol Biol Phys 84:e-271–e277Google Scholar
  21. 21.
    Pasler M, Georg D, Bartelt S et al (2013) Node-positive left-sided breast cancer: does VMAT improve treatment plan quality with respect to IMRT? Strahlenther Onkol 189:380–386Google Scholar
  22. 22.
    Polgar C, Major T, Fodor J et al (2010) Accelerated partial-breast irradiation using high-dose-rate interstitial brachytherapy: 12-year update of a prospective clinical study. Radiother Oncol 94:274–279PubMedCrossRefGoogle Scholar
  23. 23.
    Polgar C, Van Limbergen EV, Pötter R et al (2010) Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: Recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol 94:264–273PubMedCrossRefGoogle Scholar
  24. 24.
    Polgar C, Fodor J, Major T et al (2013) Breast-conserving therapy with partial or whole breast irradiation: Ten-year results of the Budapest randomized trial. Radiother Oncol 108:197–202Google Scholar
  25. 25.
    Presley CJ, Soulos PR, Herrin J et al (2012) Patterns of use and short-term complications of breast brachytherapy in the national Medicare population from 2008–2009. J Clin Oncol 30:4302–4307PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Rosenkranz KM, Tsui E, McCabe EB et al (2013) Increased rates of long-term-complications after MammoSite brachytherapy compared to whole breast radiation therapy. J Am Coll Surg 217:497–502Google Scholar
  27. 27.
    Sedlmayer F, Sautter-Bihl ML, Budach W et al (2013) DEGRO practical guidelines: radiotherapy of breast cancer I. Strahlenther Onkol 189:825–833Google Scholar
  28. 28.
    Shah C, Antonucci JV, Wilkinson JB et al (2011) Twelve-year clinical outcomes and patterns of failure with accelerated partial breast irradiation versus whole-breast irradiation: results of a matched-pair analysis. Radiother Oncol 100:210–214PubMedCrossRefGoogle Scholar
  29. 29.
    Shah S, Vicini F, Wazer DE et al (2013) The American Brachytherapy Society consensus statement for accelerated partial breast irradiation. Brachytherapy 12:267-277PubMedCrossRefGoogle Scholar
  30. 30.
    Shah C, Wilkinson JB, Lanni T et al (2013) Five-year outcomes and toxicities using 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Clin Breast Cancer 13:206–211PubMedCrossRefGoogle Scholar
  31. 31.
    Smith BD, Arthur DW, Buchholz TA et al (2009) Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 74:987–1001PubMedCrossRefGoogle Scholar
  32. 32.
    Smith GL, Xu Y, Buchholz TA et al (2012) Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA 307:1827–1837PubMedCentralPubMedGoogle Scholar
  33. 33.
    Strnad V, Hildebrandt G, Pötter R et al (2010) Accelerated partial breast irradiation: 5-year results of the German-Austrian multicenter phase II trial using interstitial multicatheter brachytherapy alone after breast-conserving surgery. Int J Radiat Oncol Biol Phys 10:1016–1020Google Scholar
  34. 34.
    Todor D, Becker S, Orton CG (2013) Brachytherapy is better than external beam therapy for partial breast irradiation—Point/Counterpoint. Med Phys. Scholar
  35. 35.
    Veronesi U, Cascinelli N, Mariani L et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. New Engl J Med 347:1227–1232PubMedCrossRefGoogle Scholar
  36. 36.
    Vicini F, Winter K, Wong J et al (2010) Initial efficacy results of RTOG 0319: three-dimensional conformal radiation therapy (3D-CRT) confined to the region of the lumpectomy cavity for stage I/II breast carcinoma. Int J Radiat Oncol Biol Phys 77:1120–1127PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Yang DS, Yoon WS, Chung SY et al (2013) Set-up uncertainty during breast radiotherapy—Image-guided radiotherapy for patients with initial extensive variation. Strahlenther Onkol 189:315–320PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Emöke Mózsa
    • 1
    • 3
  • Norbert Mészáros
    • 1
  • Tibor Major
    • 1
  • Georgina Fröhlich
    • 1
  • Gábor Stelczer
    • 1
  • Zoltán Sulyok
    • 2
  • János Fodor
    • 1
  • Csaba Polgár
    • 1
    Email author
  1. 1.Centre of RadiotherapyNational Institute of OncologyBudapestHungary
  2. 2.Centre of SurgeryNational Institute of OncologyBudapestHungary
  3. 3.Department of Radiooncology and RadiotherapyLandesklinikum Wiener NeustadtWiener NeustadtAustria

Personalised recommendations